[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008117828A1 - 即効型核酸送達用キャリアー組成物 - Google Patents

即効型核酸送達用キャリアー組成物 Download PDF

Info

Publication number
WO2008117828A1
WO2008117828A1 PCT/JP2008/055730 JP2008055730W WO2008117828A1 WO 2008117828 A1 WO2008117828 A1 WO 2008117828A1 JP 2008055730 W JP2008055730 W JP 2008055730W WO 2008117828 A1 WO2008117828 A1 WO 2008117828A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid delivery
delivery carrier
prompt
carrier composition
Prior art date
Application number
PCT/JP2008/055730
Other languages
English (en)
French (fr)
Inventor
Hirofumi Takeuchi
Yasuyuki Hira
Koji Nakano
Hidekazu Toyobuku
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2008230379A priority Critical patent/AU2008230379B2/en
Priority to JP2009506363A priority patent/JP5349293B2/ja
Priority to US12/532,949 priority patent/US9315828B2/en
Priority to RU2009139246/15A priority patent/RU2476229C2/ru
Priority to HRP20150927TT priority patent/HRP20150927T1/hr
Priority to SI200831495T priority patent/SI2140870T1/sl
Priority to PL08738918T priority patent/PL2140870T3/pl
Priority to ES08738918.5T priority patent/ES2542864T3/es
Priority to UAA200910735A priority patent/UA97143C2/ru
Priority to EP08738918.5A priority patent/EP2140870B1/en
Priority to DK08738918.5T priority patent/DK2140870T3/en
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Priority to BRPI0809634-1A2A priority patent/BRPI0809634A2/pt
Priority to HK10104730.5A priority patent/HK1139041B/en
Priority to CN200880010035.6A priority patent/CN101646443B/zh
Priority to CA002682490A priority patent/CA2682490A1/en
Priority to KR1020097021571A priority patent/KR101459391B1/ko
Priority to NZ579804A priority patent/NZ579804A/en
Priority to MX2009010336A priority patent/MX2009010336A/es
Publication of WO2008117828A1 publication Critical patent/WO2008117828A1/ja
Priority to ZA2009/06576A priority patent/ZA200906576B/en
Priority to IL201116A priority patent/IL201116A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本発明の目的は、siRNA等の核酸を動物由来細胞又は動物に投与した場合に、核酸を効率的に細胞内へ送達させることができ、しかも低毒性で安全性が高い核酸送達用キャリアー、及び該キャリアーと核酸を含有する核酸送達用組成物を提供することである。(A)ジアシルホスファチジルコリン、(B)コレステロール及びその誘導体よりなる群から選択される少なくとも１種、及び(C)脂肪族第１級アミンを組み合わせて配合して核酸送達用キャリアーを調製する。また、当該核酸送達用キャリアーと核酸を混合して、核酸送達用組成物を調製する。
PCT/JP2008/055730 2007-03-26 2008-03-26 即効型核酸送達用キャリアー組成物 WO2008117828A1 (ja)

Priority Applications (20)

Application Number Priority Date Filing Date Title
DK08738918.5T DK2140870T3 (en) 2007-03-26 2008-03-26 The carrier composition for immediate nukleinsyrefremføring
US12/532,949 US9315828B2 (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
RU2009139246/15A RU2476229C2 (ru) 2007-03-26 2008-03-26 Композиция носителя для своевременной доставки нуклеиновых кислот
HRP20150927TT HRP20150927T1 (hr) 2007-03-26 2008-03-26 Sastav nosaäśa za brzu isporuku nukleinske kiseline
SI200831495T SI2140870T1 (sl) 2007-03-26 2008-03-26 Nosilni sestavek za takojšnjo dostavo nukleinske kisline
PL08738918T PL2140870T3 (pl) 2007-03-26 2008-03-26 Kompozycja nośnikowa dla natychmiastowego dostarczania kwasu nukleinowego
ES08738918.5T ES2542864T3 (es) 2007-03-26 2008-03-26 Composición portadora de administración rápida de ácidos nucleicos
UAA200910735A UA97143C2 (ru) 2007-03-26 2008-03-26 КОМПОЗИЦИЯ НОСИТЕЛЯ ДЛЯ СВОЕВРЕМЕННОЙ ДОСТАВКИ миРНК
BRPI0809634-1A2A BRPI0809634A2 (pt) 2007-03-26 2008-03-26 COMPOSIÇÃO-VEÍCULO PARA TRANSFERêNCIA RÁPIDA DE ÁCIDOS NUCLEICOS
AU2008230379A AU2008230379B2 (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
JP2009506363A JP5349293B2 (ja) 2007-03-26 2008-03-26 即効型核酸送達用キャリアー組成物
EP08738918.5A EP2140870B1 (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
HK10104730.5A HK1139041B (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
CN200880010035.6A CN101646443B (zh) 2007-03-26 2008-03-26 速效型核酸转运用载体组合物
CA002682490A CA2682490A1 (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
KR1020097021571A KR101459391B1 (ko) 2007-03-26 2008-03-26 즉효형 핵산 송달용 캐리어 조성물
NZ579804A NZ579804A (en) 2007-03-26 2008-03-26 Prompt nucleic acid delivery carrier composition
MX2009010336A MX2009010336A (es) 2007-03-26 2008-03-26 Composicion de vehiculo de rapido suministro de acido nucleico.
ZA2009/06576A ZA200906576B (en) 2007-03-26 2009-09-21 Prompt nucleic acid delivery carrier composition
IL201116A IL201116A0 (en) 2007-03-26 2009-09-23 Prompt nucleic acid delivery carrier composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007079944 2007-03-26
JP2007-079944 2007-03-26

Publications (1)

Publication Number Publication Date
WO2008117828A1 true WO2008117828A1 (ja) 2008-10-02

Family

ID=39788561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/055730 WO2008117828A1 (ja) 2007-03-26 2008-03-26 即効型核酸送達用キャリアー組成物

Country Status (26)

Country Link
US (1) US9315828B2 (ja)
EP (1) EP2140870B1 (ja)
JP (1) JP5349293B2 (ja)
KR (1) KR101459391B1 (ja)
CN (1) CN101646443B (ja)
AR (1) AR065847A1 (ja)
AU (1) AU2008230379B2 (ja)
BR (1) BRPI0809634A2 (ja)
CA (1) CA2682490A1 (ja)
CO (1) CO6241127A2 (ja)
DK (1) DK2140870T3 (ja)
ES (1) ES2542864T3 (ja)
HR (1) HRP20150927T1 (ja)
HU (1) HUE027053T2 (ja)
IL (1) IL201116A0 (ja)
MX (1) MX2009010336A (ja)
MY (1) MY151450A (ja)
NZ (1) NZ579804A (ja)
PL (1) PL2140870T3 (ja)
PT (1) PT2140870E (ja)
RU (1) RU2476229C2 (ja)
SI (1) SI2140870T1 (ja)
TW (1) TWI428135B (ja)
UA (1) UA97143C2 (ja)
WO (1) WO2008117828A1 (ja)
ZA (1) ZA200906576B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2405001A4 (en) * 2009-03-04 2013-05-22 Hirofumi Takeuchi NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERING COMPOSITION
JP2013135623A (ja) * 2011-12-28 2013-07-11 National Cerebral & Cardiovascular Center 核酸導入剤、核酸導入方法及び細胞

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
EP2618847A4 (en) 2010-09-20 2014-04-02 Merck Sharp & Dohme NOVEL CATIONIC LIPIDS WITH LOW MOLECULAR WEIGHT FOR OLIGONUCLEOTIDE DELIVERY
WO2017187426A1 (en) 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
KR102641844B1 (ko) 2016-12-14 2024-02-28 리간달 인코포레이티드 핵산 및 단백질 페이로드 전달을 위한 방법 및 조성물

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024201A1 (fr) * 1994-03-11 1995-09-14 Yoshitomi Pharmaceutical Industries, Ltd. Preparation de liposomes
JPH10313872A (ja) * 1997-05-21 1998-12-02 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス剤
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
JP2002529439A (ja) 1998-11-12 2002-09-10 インビトロジェン コーポレイション トランスフェクション薬剤
WO2004017940A2 (en) * 2002-08-20 2004-03-04 Neopharm, Inc. Pharmaceutically active lipid based formulation of sn38
JP2005508394A (ja) 2001-11-06 2005-03-31 マイラス コーポレイション ｓｉＲＮＡ、両親媒性化合物及びポリカチオンを用いた組成物及び方法
WO2005102268A2 (de) * 2004-04-22 2005-11-03 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
JP2005336081A (ja) * 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
WO2006002538A1 (en) * 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US6358523B1 (en) * 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
US6835395B1 (en) * 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
EA008497B1 (ru) * 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
US20040208921A1 (en) * 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
MXPA05013239A (es) * 2003-06-27 2006-03-09 Sumitomo Chemical Co Compuestos de amida y metodos para controlar enfermedades vegetales con los mismos.
WO2005007196A2 (en) 2003-07-16 2005-01-27 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2005027979A2 (en) * 2003-09-17 2005-03-31 Let There Be Hope Medical Research Institute Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells
EP1759691A1 (en) 2003-11-20 2007-03-07 Delex Therapeutics Inc. Stable liposome compositions
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
CN101346468B (zh) * 2005-06-15 2016-03-30 麻省理工学院 含胺脂质和其用途
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
UA97559C2 (uk) * 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024201A1 (fr) * 1994-03-11 1995-09-14 Yoshitomi Pharmaceutical Industries, Ltd. Preparation de liposomes
JPH10313872A (ja) * 1997-05-21 1998-12-02 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス剤
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
JP2002529439A (ja) 1998-11-12 2002-09-10 インビトロジェン コーポレイション トランスフェクション薬剤
JP2005508394A (ja) 2001-11-06 2005-03-31 マイラス コーポレイション ｓｉＲＮＡ、両親媒性化合物及びポリカチオンを用いた組成物及び方法
WO2004017940A2 (en) * 2002-08-20 2004-03-04 Neopharm, Inc. Pharmaceutically active lipid based formulation of sn38
WO2005102268A2 (de) * 2004-04-22 2005-11-03 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
JP2005336081A (ja) * 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
WO2006002538A1 (en) * 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2140870A4

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2405001A4 (en) * 2009-03-04 2013-05-22 Hirofumi Takeuchi NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERING COMPOSITION
US9090912B1 (en) 2009-03-04 2015-07-28 Hirofumi Takeuchi Nucleic acid complex and nucleic acid-delivering composition
JP5808246B2 (ja) * 2009-03-04 2015-11-10 大塚製薬株式会社 核酸複合体、及び核酸送達用組成物
JP2013135623A (ja) * 2011-12-28 2013-07-11 National Cerebral & Cardiovascular Center 核酸導入剤、核酸導入方法及び細胞

Also Published As

Publication number Publication date
US9315828B2 (en) 2016-04-19
BRPI0809634A2 (pt) 2014-09-23
PL2140870T3 (pl) 2015-11-30
UA97143C2 (ru) 2012-01-10
CN101646443B (zh) 2015-01-14
PT2140870E (pt) 2015-09-15
KR20090130056A (ko) 2009-12-17
CA2682490A1 (en) 2008-10-02
HUE027053T2 (en) 2016-08-29
ES2542864T3 (es) 2015-08-12
EP2140870A4 (en) 2011-09-07
AU2008230379A1 (en) 2008-10-02
TWI428135B (zh) 2014-03-01
SI2140870T1 (sl) 2015-10-30
MX2009010336A (es) 2009-10-16
ZA200906576B (en) 2010-11-24
RU2476229C2 (ru) 2013-02-27
MY151450A (en) 2014-05-30
HK1139041A1 (en) 2010-09-10
CO6241127A2 (es) 2011-01-20
US20100063131A1 (en) 2010-03-11
KR101459391B1 (ko) 2014-11-07
IL201116A0 (en) 2010-05-17
DK2140870T3 (en) 2015-07-20
JP5349293B2 (ja) 2013-11-20
RU2009139246A (ru) 2011-05-10
NZ579804A (en) 2012-05-25
EP2140870A1 (en) 2010-01-06
EP2140870B1 (en) 2015-06-24
AU2008230379B2 (en) 2012-12-06
AR065847A1 (es) 2009-07-08
JPWO2008117828A1 (ja) 2010-07-15
HRP20150927T1 (hr) 2015-10-09
TW200902035A (en) 2009-01-16
CN101646443A (zh) 2010-02-10

Similar Documents

Publication Publication Date Title
WO2008117828A1 (ja) 即効型核酸送達用キャリアー組成物
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2010099383A3 (en) Compositions and methods for ex vivo hepatic nucleic acid delivery
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
WO2008011636A3 (en) Targeted gene delivery for dendritic cell vaccination
WO2009065561A8 (en) System for delivery into a xcr1 positive cell and uses thereof
WO2007139723A8 (en) Chemicallymodified oligonucleotide primers for nucleic acid amplification
WO2010048552A3 (en) Methods of using oligomeric compounds comprising 2'-substituted nucleosides
WO2008129548A3 (en) A system for delivering therapeutic agents into living cells and cells nuclei
EP4385568A3 (en) Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2007118245A3 (en) Methods and compositions related to adenoassociated virus-phage particles
PH12014500590A1 (en) Antimicrobial formulations with pelargonic acid
WO2007069068A3 (en) Cell penetrating peptide conjugates for delivering nucleic acids into cells
WO2009129465A3 (en) Compositions and methods for inhibiting expression of xbp-1 gene
EP2348112A3 (en) Stabilized immune modulatory RNA (SIMRA) compounds
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2011071535A3 (en) Compositions and methods for inhibiting human host cell factors required for influenza virus replication
EP2692723A8 (en) Aryloxy dihalopropenyl ether compound and use thereof
WO2009061003A3 (en) Nucleic acid complex and nucleic acid delivery composition
WO2009006446A3 (en) Methods for cloning small rna species
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2008052046A3 (en) Compositions for coating cell membranes and methods of use thereof
WO2008087774A1 (ja) 抗酸化剤
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
WO2007121054A3 (en) Nucleic acids for apoptosis of cancer cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010035.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08738918

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12009501758

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008230379

Country of ref document: AU

Ref document number: 579804

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 201116

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12532949

Country of ref document: US

Ref document number: 2009091400

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 2682490

Country of ref document: CA

Ref document number: 2009506363

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6156/DELNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/010336

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: PI20093905

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 2008738918

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008230379

Country of ref document: AU

Date of ref document: 20080326

Kind code of ref document: A

Ref document number: 20097021571

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009139246

Country of ref document: RU

Ref document number: 09120191

Country of ref document: CO

ENP Entry into the national phase

Ref document number: PI0809634

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090925